MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy

Table 1 Patient characteristics (n = 78)

Age (years)	Mean	56
	Range	24–81
Gender	Male	42 (53.8%)
	Female	36 (46.1%)
Tumor location	Frontal	20 (25.6%)
	Parietal	13 (16.6%)
	Temporal	13 (16.6%)
	Occipital	11 (14.1%)
	More than one lobe	21 (26.9%)
Duration of symptoms prior to diagnosis	< 3 months	60 (76.9%)
	≥ 3 months	18 (23.1%)
Karnofsky performance score	≥ 60	78 (100%)

ISSN: 1479-5876